Casticin suppresses the carcinogenesis of small cell lung cancer H446 cells through activation of AMPK/FoxO3a signaling

QIAN GONG1*, XIAOZHENG CAO2*, JIANGUO CAO3,4, XIAOHONG YANG3,4 and WENBIN ZENG2

1Pharmacy Department, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine; 2School of Pharmaceutical Sciences, and Molecular Imaging Research Center, Central South University; 3Department of Pharmaceutical Science, Medical College, Hunan Normal University; 4Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Changsha, Hunan 410013, P.R. China

Received January 10, 2018; Accepted June 12, 2018

DOI: 10.3892/or.2018.6547

Abstract. Casticin, a natural polymethoxyflavone isolated from A. annua, V. trifolia, and V. agnus-castus induces apoptosis in cancer cells by activating FoxO3a. However, whether casticin inhibits in vitro carcinogenesis and cancer stem cell (CSC) characteristics, and whether casticin activates FoxO3a in small cell lung cancer (SCLC) cells remain unclear. We here demonstrated that casticin decreased sphere- and colony-formation capabilities, and downregulated uPAR and CD133 in second-generation spheres, which were considered as lung cancer stem-like cells (LCSLCs), from SCLC H446 cells, in a concentration-dependent manner. In addition, casticin dose-dependently elevated the phosphorylation levels of AMPK and ACC, and reduced p-FoxO3a expression. The above effects were attenuated by AMPK knockdown with small interfering RNAs (siRNAs). FoxO3a silencing resulted in decreased protein expression of FoxO3a, increased in vitro carcinogenesis and CSC characteristics, with no appreciable effects on AMPK and ACC phosphorylation, and displayed similar activities to those neutralizing the effects of casticin on in vitro carcinogenesis and CSC characteristics. These findings reveal a novel mechanism for regulating AMPK/FoxO3a signaling in response to casticin, suggesting a new strategy for SCLC therapy by targeting cancer stem-like cells.

Introduction

Small cell lung cancer (SCLC), a poorly differentiated and highly aggressive tumor, constitutes approximately 15% of all lung cancers (1). SCLC patients often present with metastasis at diagnosis, ruling out surgery as a treatment option (2). There is currently no approved targeted drugs for SCLC, and no effective method for early diagnosis is available; meanwhile, most patients treated with conventional therapies, including chemotherapy and radiotherapy, show recurrence after a short period of time, which results in poor patient prognosis (3). To improve the survival of patients with SCLC, developing new and efficacious candidate agents is urgently required.

Emerging evidence suggests that cancer stem cells (CSCs), a subpopulation of tumor cells, have the properties of self-renewal, heterogeneous progeny, drug-resistance, and carcinogenesis in vitro and in vivo (4,5). Multiple SCLC characteristics, such as aggressiveness and high metastatic potential, suggest that this cancer could be enriched in CSCs (6). Furthermore, drug resistance may be attributable to the occurrence of a CSC subpopulation in SCLC (6). Therefore, a therapeutic strategy targeting CSCs may help cure malignant tumors, including SCLC (7).

FOXO3a is considered an evolutionarily conserved transcription factor involved in various cellular processes, including cell cycle arrest, DNA repair and tumor suppression (8). In cancer progression, FOXO3a inhibition stimulates cell transformation and angiogenesis (9). Conversely, FOXO3a overexpression suppresses cancer cell growth, induces apoptosis, and reduces tumor size by regulating downstream effectors (10). These findings suggest a tumor suppressor role for FOXO3a, which could constitute a potential target for cancer treatment. Our previous findings demonstrated that casticin, a natural polymethoxyflavone isolated from A. annua, V. trifolia, and V. agnus-castus that has been widely used in traditional Chinese medicine as an anti-inflammatory drug for thousands of years, not only induces growth suppression, apoptosis and cell cycle arrest in hepatocellular carcinoma (11) and breast cancer cells (12), but also promotes apoptosis in ovarian cancer SKOV3 cells (13) through FOXO3a activation. However, whether casticin inhibits in vitro carcinogenesis and
CSC characteristics in the SCLC H446 cell line, and activates FoxO3a remains unclear. Yung et al (9) demonstrated that AMPK activation inhibited cervical cancer cell growth through AKT/FoxO3a/FOXM1 signaling. Meanwhile, Shrestha et al (14) reported that the AMPK/FoxO3A axis plays a critical role in the antiproliferative effects of adiponectin in cancer cells. Furthermore, Sato et al proposed that metformin efficaciously eliminates glioma stem cell-like cells by activating FOXO3 via AMPK (8). Moreover, Zhao et al provided evidence that GL-V9, a new synthetic flavonoid derivative, improved the state of animals with DSS-induced colitis from oxidative stress by upregulating Trx-1 via activation of the AMPK/FoxO3a pathway (15). However, whether the anticancer effects of casticin involve AMPK/FoxO3a signaling remains undefined.

The present study showed that casticin inhibited in vitro carcinogenesis and CSC characteristics in LCSCs derived from the H446 cell line, as demonstrated by sphere- and colony-formation assays, as well as western blot analysis. Mechanistically, the effects of casticin were partly associated with activation of AMPK/FoxO3a signaling. These findings suggest that casticin may be used as a novel candidate agent for SCLC treatment targeting lung cancer stem-like cells.

Materials and methods

Cell culture and reagents. The human small cell lung cancer NCI-H446, H209 and H69 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and maintained in Dulbecco's modified Eagle's medium (DMEM, Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Shanghai, China), 100 U/ml penicillin and 100 U/ml streptomycin, in a humidified atmosphere with 5% CO2 at 37°C. Casticin (purity ≥98%) was purchased from Chengdu Biopurify Pharma Co., Ltd. (Chengdu, China), as yellow crystals (molecular weight, 374.3 Da). It was dissolved in dimethyl-sulfoxide (DMSO) to prepare a 10 mmol/l stock solution, diluted in culture cell medium immediately before use. The following reagents were purchased from Hunan Clonetimes Biotech Co., Ltd. (Changsha, China): Antibodies against AMPKα (cat. no. 2532), p-AMPK (cat. no. 8324), ACC (cat. no. 9957), FoxO3a (cat. no. 2497), p-FoxO3a (cat. no. 9465), uPAR (cat. no. 9692) and CD133 (cat. no. 3570S) (Cell Signaling Technology, Inc., Danvers, MA, USA); antibodies targeting p-ACC (cat no. sc-271965; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and human β-actin (cat no. A4700; Sigma Chemicals; Merck KGaA, Darmstadt, Germany) were employed as well. Other reagents included Invitrogen™ Lipofectamine 2000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and the growth supplements B-27 and N-2 (Invitrogen; Thermo Fisher Scientific, Inc.).

Sphere culture and self-renewal assay. To obtain spheres, the cells were cultured in stem cell-conditioned medium (DMEM/F12 medium supplemented with 0.02X B27, 20 ng/ml EGF, 20 ng/ml bFGF, 0.4% BSA, 4 µg/ml insulin, 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.) in ultra-low attachment 6-well plates (Corning Inc., Corning, NY, USA). When spheres reached ≥20 cells, the suspension cultures were passaged every six days. Spheres were counted in 10 different high power fields using an inverted microscope (Nikon TS100; Nikon, Tokyo, Japan).

For future generation of spheres in vitro, sphere cells were collected by gentle centrifugation at 200 x g for 10 min, dissociated into single-cell suspensions, and cultured to allow sphere regeneration.

To determine the sphere-formation rate, the dissociated cells or second-generation spheres treated with casticin (final concentrations of 1.0, 3.0 and 10.0 µmol/l, respectively) were seeded at a density of 1,000 cells/ml in 6-well plates to generate new spheres. The total number of spheres was recorded after 6 days of culture. Sphere formation rate was calculated by dividing the total number of spheres formed by that of live cells seeded multiplied by 100.

Clonogenic assay on soft agar. Each well of a 6-well culture plate was coated with 2 ml bottom agar-medium mixture (DMEM, 10% FBS, and 0.6% agar). After solidification, 2 ml top agar-medium mixture (DMEM, 10% FBS, and 0.3% Noble agar; BD Difco™; BD Biosciences, Franklin Lakes, NJ, USA) containing 1,000 cells/ml in 6-well plates to generate new spheres. The total number of spheres was recorded after 14 days, the colonies formed (≥20 cells) were counted under an inverted fluorescent microscope (Olympus CK40; Olympus Corp., Tokyo, Japan), with the representative views imaged. Colony formation rate was calculated by dividing the total number of colonies formed by that of live cells seeded multiplied by 100.

Silencing by siRNA. Dissociated second-generation spheres were plated at 2.5x105 cells/well in 6-well plates. After 24 h, the siRNA-negative control (si-NC; Santa Cruz Biotechnology, Inc.) and AMPK- or FoxO3a-specific siRNAs (siAMPK or siFoxO3a; Shanghai GenePharma Co., Ltd., Shanghai, China) were transfected into cells, respectively, using Invitrogen™ Lipofectamine 2000 reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Separate siRNAs were used for FoxO3a (5'-GACAUAUGACACACAGUAA-3') and AMPK (5'-GAGGAGCUUUGAUU-3') (16). On-TARGET-plus control siRNAs (Thermo Fisher Scientific, Inc.) were used as control sequences.

Western blot analysis. Western blot analysis was carried out as described by Liu et al (17). Primary antibodies raised against AMPKα, p-AMPK, FoxO3a, p-FoxO3a, uPAR, ALDH1, Bmi1, SOX2 and β-actin were used. Cells were lysed in lysis buffer for 20 min at 4°C. Protein amounts were determined with the Bio-Rad assay system (Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts (50 µg) of total protein were fractionated by SDS-PAGE and transferred onto polyvinylidene fluoride membranes (PVDF) (Millipore, Billerica, MA, USA). Signals were detected using an ECL Advance Western blot analysis system (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA). Experiments were carried out in triplicate (ImageJ v.1.84; National Institutes of Health, Bethesda, MD, USA).

Immunohistochemical (IHC) analysis. Four micron-thick tissue sections were immunostained with uPAR-specific antibody. Immunostaining was performed using a Ventana...
Discovery Ultra (Ventana Medical Systems, Tucson, AZ, USA). Antigen retrieval was performed using CC1 for 40 min at 95°C. IHC staining was followed by hematoxylin counterstaining. Slides were rinsed, dehydrated through alcohol and xylene and coverslipped.

**In vivo tumorigenesis assessment.** Twenty-four pathogen-free BALB/c-nu female mice (13-15 g) aged 4 weeks were purchased from the Animal Institute of the Chinese Academy of Medical Science (CAMS). All animal studies were performed in accordance with the standard protocols, and approved by the Ethics Committee of Hunan Normal University and the Committee of Experimental Animal Feeding and Management. Mice were randomly divided into 3 groups (4 mice/group), and maintained under standard conditions. Varying amounts of H446 cells (10^5, 10^6 and 10^7, respectively) were subcutaneously injected into 4-week-old female nude mice in the left flank; in parallel, second generation sphere-derived cells (LCSCs, 10^5, 10^6 and 10^7, respectively) were subcutaneously injected into the right flank. Tumor growth was monitored visually every week, and the maximum tumor volume allowed was consistent with the IACUC guidelines (diameter, 1.5 cm; area, 1.8 cm2; volume 1.8 cm^3). Tumor volumes were calculated in accordance with the formula: V (transplanted tumor volume, mm^3) = L (longest diameter, mm) x W (minimum diameter, mm)^2 x 0.5. After 8 weeks of tumor growth, the mice were euthanized using cervical vertebra luxation. The obtained tumor tissues were fixed in formalin and embedded in paraffin. Hematoxylin and eosin (H&E) staining and immunohistochemical analysis were performed to assess tumor histology and tumor markers in the mouse xenografts.

**Statistical analysis.** SPSS 20.0 software (IBM Corp., Armonk, NY, USA) was used for analysis. Data are expressed as the mean ± standard deviation (SD); n=number of measurements. Multiple groups were compared by one-way analysis of variance (ANOVA); comparisons of group means were performed by the LSD method for normally distributed variables. Two-tailed t-test was also used as appropriate. P<0.05 was considered statistically significant.

**Results**

**Spheres from the H446 cell line show cancer stem-like cell characteristics.** To evaluate the sphere-forming capabilities of the SCLC H446, H209 and H69 cell lines, sphere-formation rates of the three cell lines were assessed. The results showed that the sphere-forming capability of H446 cells was higher than that of both H209 and H69 cell lines (Fig. 1A). To determine the capability of H446, H209 and H69 cells for self-renewal initiation, these cells were submitted to several serial passages. As shown in Fig. 1B, sphere-formation rate was highest for second-generation spheres at the third sphere-formation process in the H446 cell line compared with other cell lines or spheres of another generation. Therefore, second-generation spheres of H446 cells were considered to be lung cancer stem-like cells (LCSCs), and used for subsequent experiments.

We next compared the *in vitro* oncogenic capabilities of LCSCs and H446 cells by sphere- and colony formation assays. The results showed that the size and population of tumor spheres from LCSCs were larger than the values obtained for H446 cells (Fig. 1C). In addition, the colony formation ability was significantly enhanced in LCSCs compared with H446 cells (Fig. 1D). These data suggested that LCSCs had the capacity of self-renewal and oncogenic capabilities *in vitro*, and were highly enriched in second-generation spheres of H446 cells.

To further confirm the stem-like properties of LCSCs, the protein expression levels of SCLC CSC-related markers were assessed in LCSCs and H446 cells. Western blot analysis demonstrated that the protein expression levels of uPAR and CD133 were higher in the LCSCs than these levels in the H446 cells (Fig. 1E).

To explore the role of AMPK/FoxO3a signaling in the *in vitro* carcinogenesis of H446-derived LCSCs, the phosphorylated protein levels of AMPK, ACC and FoxO3a were determined. As shown in Fig. 1F, the phosphorylation levels of AMPK and ACC were lower, while FoxO3a protein phosphorylation was increased, in LCSCs compared with H446 cells. These results suggest that inactivation of AMPK and FoxO3a were associated with carcinogenesis maintenance *in vitro* and the stem-like properties of H446-derived LCSCs.

In addition, the abilities of LCSCs and H446 cells to form tumors in BALB/c-nu mice were assessed. As many as 1x10^5 H446 cells were required to initiate stable tumor formation for 23-42 days after injection, while, as few as 1x10^3 LCSCs were sufficient to generate visible tumors only 19-28 days post-injection (Fig. 1G). Furthermore, H&E staining revealed similar histological characteristics in tumor xenografts derived from LCSCs and H446 cells (Fig. 1H). Furthermore, uPAR protein amounts were higher in transplanted tumors of LCSCs than those of H446 cells, as indicated by immunohistochemistry (Fig. 1H). These results provide sufficient evidence that H446 second-generation spheres possess LCSC features such as increased *in vitro* carcinogenesis and *in vivo* tumorigenic potential.

**Casticin inhibits in vitro carcinogenesis and activates AMPK/FoxO3a signaling in H446-derived LCSCs.** Similar to our previous findings (17), this study demonstrated that the indicated concentrations (1.0, 3.0 and 10.0 µmol/l) of casticin suppressed self-renewal capability by reducing the sphere-formation rate in H446-derived LCSCs (Fig. 2A), in a dose-dependent manner. In addition, colony formation assay on soft agar showed that casticin significantly inhibited the colony forming ability of H446-derived LCSCs (Fig. 2B), in a dose-dependent manner. To further confirm the inhibitory effects of casticin on CSC characteristics, we next assessed the expression levels of SCLC CSC bio-markers, including uPAR and CD133, in H446-derived LCSCs treated with casticin at the indicated concentrations. The results showed that the protein levels of uPAR and CD133 were dose-dependently reduced by casticin (Fig. 2C). Taken together, these findings demonstrated that casticin could inhibit *in vitro* carcinogenesis and CSC characteristics in H446-derived LCSCs.

To test the hypothesis that casticin inhibits *in vitro* carcinogenesis and CSC characteristics in H446-derived LCSCs through activation of AMPK/FoxO3a signaling, the effects of casticin on the phosphorylated protein levels
Figure 1. In vitro and in vivo carcinogenesis and AMPK/FoxO3a signaling activation in LCSLCs and H446 cells. (A) Representative micrographs of spheres obtained under a phase contrast microscope (magnification, x10, upper panel) and sphere-forming rates in H69, H209 and H446 cells (lower panel). *P<0.05 vs. H69 cells. P<0.05 vs. H209 cells. (B) Sphere forming rates of H69, H209, and H446 in different generations. *P<0.05 vs. first generation. *P<0.05 vs. second or fourth generation. (C) Representative micrographs of spheres obtained under a phase contrast microscope (magnification, x10, upper panel) and sphere-forming rates in LCSLCs and H446 cells (lower panel) at 3, 6 and 12 days, respectively. *P<0.05 vs. H446 cells at the same time point. *P<0.05 vs. LCSLCs at 3 days. (D) Representative micrographs of colonies obtained under a phase contrast microscope (magnification, x10, upper panel) and colony-forming rates in LCSLCs and H446 cells (lower panel). (E) Representative western blot bands (left panel), and quantitative analysis of CD133 and uPAR protein expression levels in LCSLCs and H446 cells (right panel). *P<0.05 vs. H446 cells. (F) Representative western blot bands (left panel), and phosphorylation levels of AMPKα, ACC and FoxO3a in LCSLCs and H446 cells (right panel). *P<0.05 vs. H446 cells. (G) Ability of LCSLCs and H446 cells to form tumors in BALB/c-nu mice. (H) Hematoxylin and eosin (H&E) staining and uPAR immunohistochemistry of tumor xenografts derived from LCSLCs and H446 cells. LCSLCs, lung cancer stem-like cells.
of AMPK, ACC and FoxO3a were evaluated by western blot analysis. As shown in Fig. 2D, treatment with casticin resulted in significantly elevated phosphorylation levels of AMPK and ACC, and reduced FoxO3a phosphorylation, in a concentration-dependent manner. Collectively, these findings indicated that casticin inhibited in vitro carcinogenesis and CSC characteristics of H446-derived LCSCs, likely involving the activation of AMPK/FoxO3a signaling.

Effects of AMPK silencing on in vitro carcinogenesis and AMPK/FoxO3a signaling in H446-derived LCSCs. AMPK is a central cellular energetic biosensor that regulates a broad array of cellular metabolic routes activated by nutrient deprivation, mitochondrial dysfunction, oxidative stress and cytokines (18). Previous studies have demonstrated that casticin induces apoptosis through reactive oxygen species-mediated mitochondrial signaling pathways in cervical (19) and lung (20) cancers. Therefore, we hypothesized that the inhibitory effects of casticin on H446-derived LCSCs may also involve AMPK activation. To test this, we firstly knocked down AMPK with siRNA in H446-derived LCSCs, and evaluated the phosphorylated protein levels of AMPK, ACC and FoxO3a. As shown in Fig. 3A, transfection with AMPK siRNA resulted in reduced AMPK protein expression, decreased ACC phosphorylation, and increased phosphorylation levels of FoxO3a, compared with the untreated or control siRNA-treated H446-derived LCSCs. Moreover, AMPK knockdown enhanced sphere and colony formation abilities, compared with the untreated or control siRNA-treated counterparts (Fig. 3B and C). Accordingly, the protein expression levels of uPAR and CD133 were increased in the H446-derived LCSCs transfected with AMPK siRNA compared with the untreated or control siRNA-treated counterparts (Fig. 3D). These results suggested that AMPK knockdown blocked AMPK/FoxO3a signaling, and enhanced in vitro carcinogenesis and CSC characteristics in H446-derived LCSCs.

Effects of casticin on in vitro carcinogenesis and AMPK/FoxO3a signaling activation in H446-derived LCSCs transfected with AMPK siRNA. To assess whether the inhibitory effects of casticin on oncogenicity in H446-derived LCSCs is affected by AMPK regulation, casticin (0 or 3.0 µmol/l) was administered to H446-derived LCSCs transfected with AMPK- and control siRNAs, respectively. Compared with the control siRNA group, AMPK silencing not only reduced AMPK levels and ACC phosphorylation, but also antagonized elevated phosphorylation levels of AMPK.
and ACC in response to casticin administration (3.0 µmol/l) in H446-derived LCSLCs (Fig. 4A). In addition, AMPK knockdown also elevated the phosphorylation levels of AMPKα, ACC, and FoxO3α in H446-derived LCSLCs transfected with AMPK siRNA (siAMPK) and untreated (Mock) cells or H446-derived LCSLCs transfected with control siRNA (siControl) (right panel). Furthermore, AMPK knockdown not only enhanced self-renewal and colony formation capabilities, but also counteracted the inhibitory effects of casticin on carcinogenesis in H446-derived LCSLCs in vitro (Fig. 4B and C). Meanwhile, transfection with AMPK siRNA resulted in increased uPAR and CD133 protein levels, reversing the inhibitory effects of casticin on uPAR and CD133 expression in H446-derived LCSLCs (Fig. 4D). These results suggested that AMPK activation may be upstream of FoxO3α activation in response to casticin stimulation in H446-derived LCSLCs.

Effects of FoxO3α silencing on in vitro carcinogenesis and AMPK/FoxO3α signaling activation in H446-derived LCSLCs. FoxO3α, a downstream effector of AMPK, is associated with a variety of cell processes, including cell cycle progression, apoptosis, stress, detoxification, DNA repair, glucose metabolism and differentiation (21). To assess whether the in vitro effects of casticin on carcinogenesis and CSC characteristics in H446-derived LCSLCs involve AMPK/FoxO3α signaling, FoxO3α was silenced. As shown in Fig. 5A, FoxO3α knockdown mainly resulted in decreased FoxO3α protein levels, with no effects on AMPK and ACC levels or phosphorylation. Furthermore, FoxO3α knockdown increased sphere and colony formation rates (Fig. 5B and C) as well as uPAR and CD133 protein levels (Fig. 5D) in H446-derived LCSLCs. These results indicated that activation of FoxO3α could inhibit in vitro carcinogenesis and CSC characteristics in H446-derived LCSLCs, and FoxO3α may be a downstream target of AMPK.

Effects of casticin on in vitro carcinogenesis and AMPK/FoxO3α signaling activation in H446-derived LCSLCs transfected with FoxO3α siRNA. To further assess whether the effects of casticin on in vitro carcinogenesis and CSC characteristics are mediated by AMPK/FoxO3α signaling, casticin (0 or 3.0 µmol/l) was administered to H446-derived LCSLCs transfected with FoxO3α or control siRNA. As expected, FoxO3α knockdown synergistically reduced FoxO3α protein phosphorylation, with slight effects on elevated AMPK and ACC phosphorylation levels associated with casticin (3.0 µmol/l) in H446-derived LCSLCs (Fig. 6A).
As shown in Fig. 6B and C, FoxO3a silencing neutralized the inhibitory effects of casticin (3.0 µmol/l) on sphere and colony formation abilities in H446-derived LCSLCs. Consistently, FoxO3a knockdown weakened the decreased expression levels of uPAR and CD133 observed in H446-derived LCSLCs in response to treatment with casticin (3.0 µmol/l) (Fig. 6D). These findings clearly indicated that the inhibitory effects of casticin on in vitro carcinogenesis and CSC properties were mediated by AMPK/FoxO3a signaling in H446-derived LCSLCs.

Discussion

The present study confirmed that casticin reduced the in vitro carcinogenesis and cancer stem cell (CSC) characteristics, and the molecular mechanism involved activation of AMPK/FoxO3 signaling in H446-derived lung cancer stem-like cells (LCSLCs). CSCs are a small population of tumor cells with the properties of self-renewal, multi-differentiation potential, and high aggressiveness and tumorigenesis in vivo (4–6). This study firstly examined second-generation spheres from the H446 cell line, namely, H446-derived LCSLCs, using sphere- and colony-formation assays, western blot analysis and xenografts in nude mice. The H446-derived LCSLCs were characterized by stronger sphere- and colony-forming capacities and overexpression of SCLC CSC biomarkers, including uPAR and CD133, compared with H446 cells. In addition, xenografts assays in nude mice provided important evidence that H446-derived LCSLCs had higher capability of tumorigenesis in vivo compared with H446 cells. Therefore, second-generation spheres from the H446 cell line could be considered as LCSLCs.

He et al (22) found that casticin inhibited epithelial-mesenchymal transition (EMT) in liver cancer stem cells from the SMMC-7721 cell line by downregulating Twist. He et al (23) demonstrated casticin also suppressed self-renewal ability in liver cancer stem cells from the MHCC97 cell line. Our previous study showed that casticin suppressed the self-renewal and invasion abilities of LCSLCs from NSCLC A549 cells through p-Akt downregulation (17). The present study demonstrated that casticin efficaciously reduced sphere and colony formation abilities, and downregulated SCLC CSC biomarkers such as uPAR and CD133, in H446-derived LCSLCs. These results clearly indicated that casticin reduced...
in vitro carcinogenesis and CSC characteristics in SCLC LCSLCs. However, the molecular mechanism by which casticin inhibits SCLC LCSLCs remained poorly understood.

Given that casticin suppresses cell growth in ovarian cancer (SKOV3) cells through FOXO3a activation (13), we aimed to ascertain whether casticin inhibits in vitro carcinogenesis and CSC characteristics in SCLC LCSLCs by activating FOXO3a, a transcription factor inactivated by AMPK (14-16,24). We first found that casticin significantly increased the phosphorylation levels of AMPK and ACC, in a concentration-dependent manner. These findings indicated that casticin increased AMPK activity. More importantly, AMPK knockdown not only reduced AMPK expression and ACC phosphorylation levels, but also antagonized the elevated phosphorylation levels of AMPK and ACC in response to casticin administration in H446-derived LCSLCs. Therefore, these findings suggest that AMPK activation may be required for response to casticin stimulation in H446-derived LCSLCs.

It was reported that AMPK acts as an upstream regulator of Foxo3a (8-10,14-16,24,25). This study provided several lines of evidence that casticin activates Foxo3a in an AMPK-dependent manner. Indeed, AMPK knockdown resulted in elevated phosphorylation levels of Foxo3a, and attenuated the decreased Foxo3a phosphorylation associated with casticin administration in H446-derived LCSLCs. In addition, Foxo3a silencing mainly led to decreased Foxo3a protein levels, with no effects on AMPK and ACC expression and phosphorylation associated with casticin administration. Mechanistically, casticin had no effect on AMPK protein expression, but suppressed AMPK-mediated Foxo3a phosphorylation. Functionally, Foxo3a knockdown mimicked the effects AMPK knockdown on sphere- and colony-forming capabilities, as well as on protein expression levels of the CSC markers uPAR and CD133, in H446-derived LCSLCs. These findings suggest that the inhibitory effects of casticin on in vitro carcinogenesis and CSC properties may be mediated by activation of AMPK/Foxo3a signaling in H446-derived LCSLCs.

Overexpression of uPAR is strongly correlated with the malignant cancer phenotype and poor prognosis (26,27). In breast cancer, elevated uPAR expression is an independent prognostic marker of reduced relapse-free survival (27). Consistently, high uPAR levels in primary tumors indicate aggressive gastric cancer (28). LeBeau et al and others...
demonstrated that a stem cell-like cell population may be enriched in spheres expressing the uPAR cell surface marker in H446 cells (27,29). Furthermore, inhibition of uPAR results in prominently increased p27Kip1 expression, which correlates with decreased p-PI3K and p-AKT levels, as well as increased FOXO3a protein amounts (30,31). The current findings suggest that the inhibitory effects of casticin on in vitro carcinogenesis and CSC properties involve uPAR downregulation. However, the interaction of FoxO3a with uPAR warrants further investigation.

In summary, this study firstly provided evidence that AMPK plays a role in regulating in vitro carcinogenesis and CSC properties by activating FoxO3a in H446-derived LCSLCs. In addition, the above findings indicated that the inhibitory effects of casticin on in vitro carcinogenesis and CSC properties in H446-derived LCSLCs, including sphere and colony formation abilities, and increased levels of CSC biomarkers (e.g., uPAR and CD133), are associated with activation of AMPK/FoxO3a signaling. Overall, this study raises the novel and intriguing idea that interventions to modulate AMPK, a known cellular metabolic sensor by casticin, could contribute to preventing and treating human SCLC by targeting LCSLCs.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Project of NSFC (nos. 30760248 and 81172375), the Project of Scientific Research of Hunan Province, granted by the Health and Family Planning Commission of Hunan Province (no. B2013-098).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

Professor JC conceived and designed the study. QG, XC and XY performed the experiments. QG and XC wrote the manuscript. Professor JC and WZ reviewed and edited the manuscript. Professor WZ was also involved in the conception of the study. All authors read and approved the manuscript.
and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

All animal studies were performed in accordance with the standard protocols, and approved by the Ethics Committee of Hunan Normal University and the Committee of Experimental Animal Feeding and Management.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

References